November 12 , 2004

MGH to develop tuberous sclerosis facility

Through a generous $6 million contribution from Carol and James Herscot to the MGH, the hospital will create a new center benefiting children, adults and families touched by tuberous sclerosis complex (TSC). Once established, the center will be one of the world's most sophisticated and comprehensive TSC facilities.

Tuberous sclerosis complex is a disorder with a wide range of potentially devastating symptoms affecting several organ systems, including the brain, skin, eyes, heart, lungs and kidneys. Although genetically inherited, TSC can affect individuals quite differently, even within a family. While epilepsy and benign tumors are the most common disabilities, secondary complications include memory and attention problems, depression and social isolation. TSC is one of the single largest causes of autism. It is more common than muscular dystrophy and cystic fibrosis.

Led by Elizabeth A. Thiele, MD, PhD, director of the Epilepsy Service at MassGeneral Hospital for Children and one of the nation's foremost TSC experts, the new center will feature state-of-the-art clinical facilities in the hospital's new Yawkey Center, collaborative research initiatives within the hospital and among the broader Harvard medical community, and
educational programs for medical students, advanced trainees and practicing physicians. Clinical care for children and adults will be enhanced by the addition of medical specialists and nurse coordinators who will help maintain a seamless network of primary and specialty care. The center will play a lead role in increasing the visibility of TSC worldwide.

Real estate developer James Herscot and his wife Carol have dedicated their lives to advancing TSC research and treatment. Previous gifts from the Herscot family to the MGH have been instrumental in allowing Thiele and her colleagues to advance vital research studies and further the development of a unique TSC patient database.